Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person15
Arbutus Biopharma Corp
Company
Cue Biopharma, Inc.
Company
AYTU BIOPHARMA, INC
Company
AEON Biopharma, Inc.
Company
ABVC BIOPHARMA, INC.
Company
ArriVent BioPharma, Inc.
Company
GT Biopharma, Inc.
Company
NUTRA PHARMA CORP
Company
CRESCENT BIOPHARMA, INC.
Company
Immix Biopharma, Inc.
Company
biote Corp.
Company
SUTRO BIOPHARMA, INC.
Company
Zenas BioPharma, Inc.
Company
Vitro Biopharma, Inc.
Company
Regen BioPharma Inc
Company
Primary record15
Arbutus Biopharma Corp filed SCHEDULE 13G/A
0002012383-26-003716.txt : 20261027 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0002012383 XXXXXXXX LIVE 2 Common Stock 09/30/2026 0001447028 Arbutus Biopharma Corp 03879J100 701 Veterans Circle Warminster PA 1
Arbutus Biopharma Corp filed 8-K
Item 8.01. Other Events. On October 22, 2026, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational
Arbutus Biopharma Corp filed SCHEDULE 13G/A
Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-10-07.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-10-07.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-10-07.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-10-07.
Arbutus Biopharma Corp filed SCHEDULE 13D/A
, as amended, this Amendment No. 14 ("Amendment No. 14") amends certain items of the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 16, 2015, as amended by Amendments No. 1 through 13
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-10-05.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-09-23.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-09-23.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-09-23.
Arbutus Biopharma Corp filed 4
SEC form 4 filed by Arbutus Biopharma Corp (CIK 1447028) on 2026-09-23.
Arbutus Biopharma Corp filed SCHEDULE 13G
, as amended (the "Exchange Act"). As of September 4, 2026, the Reporting Persons no longer held securities of the Issuer with a purpose or effect of changing or influencing control of the Issuer, or in connection with o
Arbutus Biopharma Corp filed 8-K
Item 8.01 Other Events. On August 21, 2026, Arbutus Biopharma Corporation (the Company ) issued a press release announcing its plans to launch a modified Dutch auction tender offer to purchase up to US$230 million in val